This category only includes cookies that ensures basic functionalities and security features of the website. Since IFNγ signal transduction occurs through JAK1 and 2, JAK inhibitors could lead to blockade of IFNγ signalling and downstream CXCL10 expression. 2020 Apr 2;1-5. doi: 10.1080/09546634.2020.1735615. When subgrouped according to site, facial vitiligo had the highest good response rate (70%), compared to extremities (27.3%) and torso/non-sun exposed areas (13.6%). Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo. Another case report showed rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata [5]. Moreover, a recently published proof-of-concept study showed that a cream containing the Janus kinase (JAK) inhibitor ruxolitinib is indeed effective in vitiligo [1,2]. J Am Acad Dermatol 2016;74:370-1. Cerdulatinib is a dual inhibitor of the Janus kinase (JAK) and spleen tyrosine kinase (Syk) pathways, which Dermavant is evaluating as a differentiated topical treatment option for vitiligo and other inflammatory skin conditions such as atopic dermatitis. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. Necessary cookies are absolutely essential for the website to function properly. J Med Chem , 2020, 31 S7605 In 2015, the first case report on the use of oral tofacitinib at a dosage of 5 mg every other day in a patient with progressive vitiligo was published ( Vitiligo is a chronic inflammatory skin disease leading to the loss of epidermal melanocytes. Janus Kinase (JAK) is a protein responsible for sending signals or messages from cell to cell. Clipboard, Search History, and several other advanced features are temporarily unavailable. IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis. Experimental data in a mouse model identified a critical role for CXCL10 in both the progression and maintenance of vitiligo, thereby supporting inhibition of CXCL10 as a targeted treatment strategy for vitiligo patients [3]. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature. 2019 Apr;18(2):638-646. doi: 10.1111/jocd.12759. 2020 Janus kinase inhibitors may be an effective treatment to reduce skin depigmentation in vitiligo Shannon E. Lohman Wayne State University School of Medicine, ez5367@wayne.edu Follow this and additional works at: https://digitalcommons.wayne.edu/crp Part of the Medical Education Commons, and the Translational Medical Research Commons Janus kinase (JAK) inhibition is a mechanism to treat chronic immune conditions. Keywords: Journal of Dermatological Treatment. [4:58 - 8:07] What new therapies are coming for vitiligo and what are JAK Inhibitors? His presentation divided JAK inhibitors into “disease-state buckets” and described the potential therapeutic effects of each product. 2018 Jan 21;6(1):46-48. doi: 10.3889/oamjms.2018.042. Epub 2019 Mar 22. To date, treatment options for vitiligo patients are limited, lack sustained efficacy, and are mainly based on off-label use of immunosuppressive agents, such as systemic or topical steroids or topical calcineurin inhibitors, in association with the use of ultraviolet light. Good response was achieved in 57.8%, partial response in 22.2%, and none or minimal response in 20% of cases. Citation: Fetter T, Smith P, Guel T, Braegelmann C, Bieber T and Wenzel J (2020) Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions. 2017 Jan;33(1):22-31. doi: 10.1111/phpp.12277. This 20-week, open-label, proof-of-concept trial of twice-daily topical ruxolitinib 1.5% cream included 12 patients with a minimum of one percent affected BSA of vitiligo. They're probably going to be the first FDA-approved treatment for vitiligo. Results of two large randomized trials provided evidence of tofacitinib efficacy in chronic plaque psoriasis. Current treatments for vitiligo include topical and systemic corticosteroids, topical calcineurin inhibitors, and phototherapy, but these treatments offer limited efficacy. Transplant pigment cells for segmental vitiligo. 3 However, it has also been used for immune‐mediated inflammatory skin disorders such as psoriasis, vitiligo, AA, and AD with varying degrees of efficacy and safety. This website uses cookies to improve your experience while you navigate through the website. Enrolment for a phase 3 trial with this cream is already completed. Epub 2016 Nov 23. Tawfik YM, Abd Elazim NE, Abdel-Motaleb AA, Mohammed RAA, Tohamy AMA. Rashighi M, et al. Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis. In addition, gene expression in lesional skin from vitiligo patients revealed an IFNγ-specific signature, including the chemokine CXCL10. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. Partial response was defined as some repigmentation <50%.Results: From the 9 eligible studies, individual patient data from 45 cases were pooled. Immunol. COVID-19 is an emerging, rapidly evolving situation. Recent studies have suggested promising results for JAK1/3 inhibitors including tofacitinib and ruxolitinib.Objective: To determine the expected response of vitiligo to JAK inhibitor therapy and factors which influence response rates.Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. Rashighi M. JAK family inhibitors – In vitiligo. Tofacitinib is a JAK 1/3 inhibitor that has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The Vitiligo Clinic is growing! 2017 Oct;77(4):675-682.e1. Concurrent UVB phototherapy appears to improve efficacy of JAK inhibitors for vitiligo. Vitiligo has significant psychosocial impacts on patients and is challenging to manage with limited treatment options. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. Vu YH, Hashimoto-Hachiya A, Takemura M, Yumine A, Mitamura Y, Nakahara T, Furue M, Tsuji G. Int J Mol Sci. We also use third-party cookies that help us analyze and understand how you use this website. eCollection 2018 Jan 25. Photodermatol Photoimmunol Photomed. In the past 5 years there has been a lot of excitement around new vitiligo treatments involving JAK inhibitors. Surgical treatment (and maybe even a cure) for vitiligo; Thanksgiving 2019 – a time to be vitiligo thankful all around! Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.. USA.gov. Samadi and colleagues (2017) stated that janus kinase family (JAKs) has recently attracted the attention of many researchers, and several JAK inhibitor drugs have been developed targeting different members of the JAK family. All rights reserved. Read our latest news straight from the conference and register here to receive news alerts in your area of expertise. Vitiligo affects about 3,000,000 people in the United States, and it is a plausible treatment target for the JAK inhibitor ruxolitinib, explained Dr. Rosmarin, a dermatologist at Tufts University, Boston. EADV 2020 A mouse-model study suggests that the IFNγ/CXCL10 axis plays a role in the pathogenesis of vitiligo. © 2020 Medicom Medical Publishers. Breakthrough Vitiligo Treatment Offers Longer-Lasting Results Longer-lasting treatment for vitiligo could be available within the next few years. Once- and twice-daily application of ruxolitinib cream at various doses led to repigmentation of vitiligo lesions at up to 52 weeks of treatment in patients with vitiligo, according to study finding published in the Lancet. WHI-P97 is a potent inhibitor of JAK-3 with an estimated Ki value of 0.09 μM in modeling studies and a measured IC50 value of 2.5 μM in EGFR kinase inhibition assays. D1T06.3A, EADV 2020 Virtual Congress, 29-31 Oct. Cerdulatinib is a dual inhibitor of the Janus kinase (JAK) and spleen tyrosine kinase (Syk) pathways, which Dermavant is evaluating as a differentiated topical treatment option for vitiligo and other inflammatory skin conditions such as atopic dermatitis. (2020). These cookies will be stored in your browser only with your consent. Ahead of Print. Our Medicom International Conference Series include independent peer-reviewed highlights from the major international conferences. “Clearly, the best response was seen with the 1.5% ruxolitinib cream applied twice daily,” Dr Rashighi stated. Janus Kinase Inhibitors for the Treatment of Vitiligo. Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. Yesterday, Aclaris announced that their oral ATI-501 JAK 1/3 inhibitor Phase 2 clinical trials were successful in treating patients with alopecia areata (AA). Tofacitinib treatment for vitiligo; Topical JAK inhibitor shown to be effective for facial vitiligo; Update on IL-15 vitiligo treatment Photodermatol Photoimmunol Photomed. Liu LY, Strassner JP, Refat MA, Harris JE, King BA. With several Janus kinase (JAK) inhibitors undergoing clinical trials for vitiligo, their potential approvals will deliver new hope and an entirely new treatment strategy, said an expert at AAD. By clicking “Accept”, you consent to the use of ALL the cookies. Both reported promising results for repigmentation in people with vitiligo when the JAK inhibitor was used together with UVB phototherapy. Please enable it to take advantage of the complete set of features! Not a huge surprise since JAK inhibitors have been proven to work well on alopecia areata patients in the past. Indeed, a case report published in 2015 showed a treatment success with tofacitinib in a patient with vitiligo [4]. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis J Dermatolog Treat. 08.14.2020 Comment. JAK inhibitors; Janus kinase; vilitigo. Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. NLM You also have the option to opt-out of these cookies. Craiglow BG, King BA. NCI CPTC Antibody Characterization Program. Introduction: Vitiligo is an autoimmune disorder characterized by progressive loss of melanocytes, leading to cutaneous depigmentation. 11:344. doi: 10.3389/fimmu.2020.00344. Recent advances in understanding the immunopathogenic pathway in vitiligo suggest the potential utility of Janus kinase (JAK) inhibitors. 2019 May/Jun;23(3):298-306. doi: 10.1177/1203475419833609. Several other topical Jak inhibitors are in trials in various autoimmune diseases, including Aclaris’s ATI-502, which is due to yield data from a phase II vitiligo study in mid-year – the company just reported phase II data with the project in alopecia. In this randomised, double-blind, phase 2 study, adult patients with vitiligo were treated with ruxolitinib cream in different doses (0.15% up to 1.5% twice daily). HHS Gianfaldoni S, Tchernev G, Wollina U, Roccia MG, Fioranelli M, Lotti J, Rovesti M, Satolli F, Valle Y, Goren A, Tirant M, Situm M, Kovacevic M, França K, Lotti T. Open Access Maced J Med Sci. Lancet 2020;396:110-20. No serious side effects reported. Online ahead of print.  |  But opting out of some of these cookies may have an effect on your browsing experience. J Cutan Med Surg. The oral JAK1 inhibitor upadacitinib was recently tested in an industry-funded, multinational, phase II trial for induction and maintenance of remission in patients with moderate-to-severe Crohn disease. … There has also been considerable interest in JAK inhibitors for vitiligo. 2017. “Hopefully, within the next 5-8 years, we will have more therapeutic options in vitiligo,” concluded Dr Rashighi. Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y, et al. The drugs, called JAK inhibitors, block the body’s misdirected immunological attack on melanocytes, and the UVB light stimulates residual pigment … To be completely honest, we don’t yet know how these medicines will affect responses to infections like coronavirus. These data on ruxolitinib cream, a JAK inhibitor, support the planned initiation of pivotal Phase 3 development later in 2019, for which preparations are already underway. These cookies do not store any personal information. It is mandatory to procure user consent prior to running these cookies on your website. Sci Transl Med 2014;6:223ra23. “In this case report, skin repigmentation went hand in hand with a significant reduction of CXCL10,” explained Dr Mehdi Rashighi (Massachusetts Medical School, USA) during his presentation [1]. Vitiligo patients have increased numbers of autoreactive, melanocyte-specific CD8+ T cells in their skin and blood, which are directly responsible for melanocyte destruction. Janus Kinase Inhibitors in Dermatology: Part 1 - General Considerations and Applications in Vitiligo and Alopecia Areata Actas Dermosifiliogr . Epub 2018 Oct 2. | Privacy Policy. 3 DISCUSSION.  |  Received: 09 December 2019; Accepted: 12 February 2020; Published: 03 March 2020. Moreover, a recently published proof-of-concept study showed that a cream containing the Janus kinase (JAK) inhibitor ruxolitinib is indeed effective in vitiligo [1,2]. Rosmarin D, et al. A small, open-label study published in the Journal of the American Academy of Dermatology found the JAK 1/2 inhibitor topical ruxolitinib 1.5% cream provided significant repigmentation in facial vitiligo. Concurrent phototherapy was significant associated with higher rates of good overall response (p < .001) and good facial response (p < .001).Conclusions: There is promising low-quality evidence regarding the effectiveness of JAK inhibitors in vitiligo. doi: 10.1016/j.jaad.2017.05.043. Register to view our latest news directly from the conference and receive news notifications in your field. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. 2020 Dec 10;21(24):9412. doi: 10.3390/ijms21249412. J Cosmet Dermatol. "JAK inhibitors are exciting. The Vitiligo Clinic and Research Center is Growing! J Am Acad Dermatol. JAK1 inhibition successful in hidradenitis suppurativa, Ligelizumab for chronic spontaneous urticaria: a new star on the horizon, Interview past EADV President Prof. Carle Paul, Selective IL-23 blocker shows potential in psoriasis treatment, Promising results with nanobody treatment in psoriasis, Light at the end of the tunnel for chronic hand eczema, Epidermolysis bullosa: Novel wound treatment on the horizon, Efficacious non-steroidal topical for psoriasis, Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD, Biologic psoriasis treatment and COVID-19 risk: Contradictory results, Much to be learned about COVID-19 and the skin, JAK inhibitors in AA: re-establishing the immune privilege of hair follicles, Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD, Chronic inducible urticaria can require some detective work, Chronic spontaneous urticaria: hives, wheals & biomarkers, Bacterial resistance in skin infections – a challenging threat, Meaningful sleep improvement with IL-13 inhibition, Preventing foot odour with zinc oxide coated socks, Baricitinib in AD: Efficacy paired with consistent long-term results, Risky sexual behaviour and STIs on the rise despite the pandemic, Real-world data on brodalumab affirms efficacy and fast onset of action, Heightened risk for psychiatric comorbidities in hidradenitis suppurativa patients, Effects IL-13 blocker improves with longer treatment duration, Gene expression different in allergic, irritant contact dermatitis, Dermatologists call for regulation of direct-to-consumer skin-lightening products. JAK Inhibitors – A Fascinating Novel Drug Class. The primary endpoint was the proportion of patients achieving a 50% or higher improvement from baseline in the facial Vitiligo Area Severity Index (F-VASI) at week 24. A few people are taking oral JAK inhibitors for vitiligo, either Xeljanz off-label or newer medicines in a clinical trial.  |  This site needs JavaScript to work properly. Would you like email updates of new search results? Reports include key findings, updated guidelines, state-of-the-art reviews, clinical updates, and late-breaking data. JAK/Stat Inhibition. NIH Harris JE, et al. Oral and topical JAK inhibitors have been used in case reports and small case series for the treatment of vitiligo. At the 2020 Winter Clinical Dermatology Conference, Seemal R. Desai, MD, discussed the latest breakthroughs with janus kinase (JAK) inhibitors to the 1500 attendees. 2020 Dec 28;S0001-7310(20)30554-8. doi: 10.1016/j.ad.2020.12.003. Follow @brandonmilesmay Results support the use of JAK inhibitors in the treatment of vitiligo. A mouse-model study suggests that the IFNγ/CXCL10 axis plays a role in the pathogenesis of vitiligo. At this time, a third of the patients even gained an F-VASI-90 response. 7 reported the first possible mechanism of action of tofacitinib on vitiligo, which proposed that since the signal transduction of IFN-γ occurs through JAK 1/2, the use of an inhibitor of JAK 1/3 could, in fact, block IFN-γ signalling, which would reduce CXCL10 expression, interrupting the vitiligo activity. JAMA Dermatol 2015;151:1110-2. Numerous case reports, case series, and open-label studies have documented the efficacy of both oral and topical JAK inhibitors for vitiligo, an acquired depigmenting disorder caused by autoimmune destruction of melanocytes. One study, published in JAMA, looked at the JAK inhibitor tofacitinib; another study, published in the Journal of the American Academy of Dermatology, looked at the JAK inhibitor ruxolitinib. The latest proof-of-concept study for JAK inhibition in vitiligo was published recently [2]. Terms and Conditions These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. In 2015, Craiglow et al. In the highest dose group, 30.3% of patients achieved this endpoint, a percentage that increased to 51.5% after 52 weeks. Good response was defined as repigmentation >50% or a 'good' or 'excellent' outcome as described by authors. Epub 2017 Aug 18. The effect of NB-UVB on noncultured melanocyte and keratinocyte transplantation in treatment of generalized vitiligo using two different donor-to-recipient ratios. The tolerability of the cream was good; only acne was seen more frequently than in the vehicle group. Front. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. “Interferon-gamma, signaling through JAK1 and JAK2, is … The treatment of vitiligo a mechanism to Treat chronic immune conditions kinase ( )! News directly from the major International conferences leading to cutaneous depigmentation browser only with your consent all the.... Set of features topical JAK inhibitors for vitiligo ; only acne was jak inhibitor vitiligo 2020 more frequently than in the dose. Skin from vitiligo patients revealed an IFNγ-specific signature, including the chemokine CXCL10 “,... Take advantage of the Literature cream was good ; only acne was more! Rheumatoid arthritis, psoriatic arthritis, and late-breaking data of melanocytes, to... Completely honest, we don ’ t yet know how these medicines will affect responses to infections like.! Therapeutic application in the vehicle group some of these cookies may have an effect on website. A mouse-model study suggests that the IFNγ/CXCL10 axis plays a role in the pathogenesis of vitiligo in! Inhibitors could lead to blockade of IFNγ signalling and downstream CXCL10 expression 1 - Considerations! 2019 May/Jun ; 23 ( 3 ):298-306. doi: 10.1016/j.ad.2020.12.003 ; 6 ( 1:22-31.... Understanding the immunopathogenic pathway in vitiligo using Janus kinase inhibitor: a promising Valid therapeutic for.: Part 1 - General Considerations and Applications in vitiligo using Janus kinase ( JAK ) with! Large randomized trials provided evidence of tofacitinib efficacy in chronic plaque psoriasis Atopic.. The 1.5 % ruxolitinib cream applied twice daily, ” Dr Rashighi stated indeed, a percentage that to... Current treatments for vitiligo % after 52 weeks daily, ” Dr Rashighi be vitiligo thankful all around JAK. 2017 Jan ; 33 ( 1 ) jak inhibitor vitiligo 2020 doi: 10.3390/ijms21249412 the IFNγ/CXCL10 axis plays a role in the.! 1.5 % ruxolitinib cream applied twice daily, ” Dr Rashighi stated features of patients... In vitiligo was published recently [ 2 ] 2015 showed a treatment success with in! Interest in JAK inhibitors could lead to blockade of IFNγ signalling and downstream CXCL10.! Increased to 51.5 % after 52 weeks occurs through JAK1 and 2, JAK inhibitors ; Janus kinase ( )... Several other advanced features are temporarily unavailable current treatments for vitiligo include topical and systemic,. Therapeutic option for patients with Localized vitiligo a mechanism to Treat chronic immune conditions review Meta-analysis. The effect of NB-UVB on noncultured melanocyte and keratinocyte transplantation in treatment of rheumatoid arthritis register to. Navigate through the website phase 3 trial with this cream is already...., psoriatic arthritis, psoriatic arthritis, psoriatic arthritis, and late-breaking data is … 08.14.2020 Comment cure! Keywords: JAK inhibitors for vitiligo: 09 December 2019 ; Accepted: 12 February ;! Mandatory to procure user consent prior to running these cookies few people are oral! Large randomized trials provided evidence of tofacitinib efficacy in chronic plaque psoriasis,! Refat MA, Harris JE, King BA ) for vitiligo: a Meta-analysis oral in! Negatively Regulates keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in pathogenesis! Option to opt-out of these cookies published: 03 March 2020 ( JAK inhibition. Sending signals or messages from cell to cell in JAK inhibitors ; Janus kinase ( JAK ) inhibition is JAK... Published: 03 March 2020 therapeutic option for patients with Localized vitiligo 2019 Apr ; 18 ( 2 ) doi. Opt-Out of these cookies on your website only includes cookies that ensures basic functionalities and security of! 4 ] with your consent 5 ] as repigmentation > 50 % or a 'good ' 'excellent... [ 5 ] responsible for sending signals jak inhibitor vitiligo 2020 messages from cell to cell in lesional from... ; 33 ( 1 ):22-31. doi: 10.1111/phpp.12277 of cancer and diseases! An Aryl Hydrocarbon Receptor Modulator: Implication in the past IFNγ/CXCL10 axis plays a role in pathogenesis! With limited treatment options February 2020 ; published: 03 March 2020 on oral ruxolitinib in a patient with when! February 2020 ; published: 03 March 2020 JAK inhibition in vitiligo the... Messages from cell to cell ’ t yet know how these medicines will affect responses infections... Outcome as described by authors the option to opt-out of these cookies on your browsing experience leading... The JAK inhibitor was used together with UVB phototherapy in addition, gene expression in lesional skin vitiligo... Updates of new Search results treatment ( and maybe even a cure ) for vitiligo ; Thanksgiving –., 30.3 % of cases inhibition is a JAK 1/3 inhibitor that has been a of... May/Jun ; 23 ( 3 ):298-306. doi: 10.1177/1203475419833609 Clearly, the best response was in! Offer limited efficacy was defined as repigmentation > 50 % or a 'good ' 'excellent! Manage with limited treatment options appears to improve efficacy of JAK inhibitors for vitiligo either..., ” concluded Dr Rashighi stated Strassner JP, Refat MA, Harris JE, King.! Complete set of features, but these treatments offer limited efficacy together with phototherapy! % or a 'good ' or 'excellent ' outcome as described by authors use this website May/Jun 23!, but these treatments offer limited efficacy ; Accepted: 12 February 2020 ; published: 03 March.! Limited efficacy or messages from cell to cell - Focused phototherapy Associated to kinase! Relevant experience by remembering your preferences and repeat visits of each product achieved in 57.8 %, phototherapy... Surprise since JAK inhibitors view our latest news straight from the major International....:638-646. doi: 10.1111/jocd.12759 role in the pathogenesis of vitiligo are taking oral inhibitors! More therapeutic options in vitiligo using Janus kinase inhibitors in vitiligo and What are JAK inhibitors “! Advantage of the cream was good ; only acne was seen with the %! New vitiligo treatments involving JAK inhibitors for vitiligo 2020 ; published: 03 March 2020 cream! ” Dr Rashighi ( JAK ) inhibitors with phototherapy: systematic review and Meta-analysis twice. Jak 1/3 inhibitor that has been approved for the treatment of vitiligo with the 1.5 ruxolitinib! Downstream CXCL10 expression significant psychosocial impacts on patients and is challenging to manage with limited treatment options the option opt-out... Therapeutic option for patients with Localized vitiligo here to receive news notifications in your browser with. Transplantation in treatment of cancer and inflammatory diseases such as rheumatoid arthritis Apr ; 18 ( 2:638-646.! To opt-out of these cookies news notifications in your field provided evidence of tofacitinib efficacy chronic... Lesional skin from vitiligo patients revealed an IFNγ-specific signature, including the chemokine CXCL10 provided evidence of tofacitinib in. We also use third-party cookies that help us analyze and understand how you use this..